{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-207867","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.579170+00:00","generated_at":"2026-06-24T06:32:13.115066+00:00","sec_items":["2.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cortexyme rebrands as Quince Therapeutics, shifts to bone-targeting drugs, reports $105M cash","bullets":["Cash, cash equivalents and short-term investments: ~$105M as of June 30, 2022 (preliminary).","Name changed from Cortexyme to Quince Therapeutics; ticker changes from CRTX to QNCX effective Aug 1, 2022.","Strategic focus on bone-targeting drug platform and lead molecule NOV004; Phase 1 clinical studies expected in 2023.","Plans to in-license or acquire clinical-stage assets for debilitating/rare diseases and out-license legacy neuroscience assets.","Cash runway expected to fund operations into second half of 2025; corporate restructuring completed in H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-207867","json":"https://secwatch.observer/filing/0001193125-22-207867.json","markdown":"https://secwatch.observer/filing/0001193125-22-207867.md","text":"https://secwatch.observer/filing/0001193125-22-207867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522207867/0001193125-22-207867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522207867/d346512d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:32:13.115066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}